PMP22 and Charcot-Marie-Tooth disease type 1A: The development of antisense oligonucleotides (ASO) targeting PMP22 expression would constitute an ideal and reliable strategy to treat CMT1A, with the main warning to not exceed in PMP22 repression to avoid the induction of a HNPP-like disease [141].